tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

CYTK Stock Latest News

Cytokinetics price target raised to $56 from $52 at BofA
The FlyCytokinetics price target raised to $56 from $52 at BofA
3d ago
CYTK
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
PremiumRatings
Promising Trial Results and Safety Profile of Aficamten Boost Cytokinetics’ Stock Outlook
5d ago
CYTK
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
PremiumRatings
Promising Data from HFSA and Long-term Efficacy of Aficamten Lead to Buy Rating for Cytokinetics
5d ago
CYTK
Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
PremiumRatings
Cytokinetics’ Aficamten Shows Superior Efficacy in Phase 3 MAPLE-HCM Trial, Boosting Stock Outlook
6d ago
CYTK
Cytokinetics presents data related to aficamten at HFSA Meeting 2025
PremiumThe Fly
Cytokinetics presents data related to aficamten at HFSA Meeting 2025
6d ago
CYTK
Positive Outlook and Buy Rating for Cytokinetics Amid Strategic Advancements and Financial Strengthening
PremiumRatingsPositive Outlook and Buy Rating for Cytokinetics Amid Strategic Advancements and Financial Strengthening
12d ago
CYTK
Cytokinetics price target raised to $80 from $74 at B. Riley
Premium
The Fly
Cytokinetics price target raised to $80 from $74 at B. Riley
13d ago
CYTK
Cytokinetics’ Strategic Financial Maneuvers and Regulatory Advancements Justify Buy Rating
Premium
Ratings
Cytokinetics’ Strategic Financial Maneuvers and Regulatory Advancements Justify Buy Rating
13d ago
CYTK
Cytokinetics Faces Lawsuit Over Misleading Investors
PremiumClass Action
Cytokinetics Faces Lawsuit Over Misleading Investors
16d ago
CYTK
Morning Movers: Workday surges after Elliot stake, stock buyback program
PremiumThe Fly
Morning Movers: Workday surges after Elliot stake, stock buyback program
18d ago
GIS
BABA
Cautious Outlook on Cytokinetics: Hold Rating Amid Competitive Challenges and Uncertain Commercial Impact
PremiumRatings
Cautious Outlook on Cytokinetics: Hold Rating Amid Competitive Challenges and Uncertain Commercial Impact
18d ago
CYTK
Cytokinetics Discusses Aficamten with FDA in Late Cycle Meeting
PremiumCompany Announcements
Cytokinetics Discusses Aficamten with FDA in Late Cycle Meeting
18d ago
8K
CYTK
Cytokinetics announces private placement of $550M of convertible senior notes
PremiumThe FlyCytokinetics announces private placement of $550M of convertible senior notes
18d ago
CYTK
Cytokinetics’ COMET-HF Study: A Potential Game-Changer for Heart Failure Treatment?
Premium
Company Announcements
Cytokinetics’ COMET-HF Study: A Potential Game-Changer for Heart Failure Treatment?
27d ago
CYTK
Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Conditions
Premium
Company Announcements
Cytokinetics’ Aficamten Study: A Potential Breakthrough for Pediatric Heart Conditions
28d ago
CYTK
Cytokinetics price target raised to $52 from $45 at BofA
PremiumThe Fly
Cytokinetics price target raised to $52 from $45 at BofA
1M ago
CYTK
Buy Rating Justified for Cytokinetics Due to Aficamten’s Advantages in HCM Treatment
PremiumRatings
Buy Rating Justified for Cytokinetics Due to Aficamten’s Advantages in HCM Treatment
1M ago
CYTK
Cytokinetics price target raised to $80 from $60 at Evercore ISI
PremiumThe Fly
Cytokinetics price target raised to $80 from $60 at Evercore ISI
1M ago
BMY
CYTK
‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results
PremiumMarket News
‘Little Room Left for Doubt’: Cytokinetics (CYTK) Stock Soars on Successful Trial Results
1M ago
RY
BAC
Cytokinetics Highlights Aficamten Data at ESC Congress
PremiumCompany AnnouncementsCytokinetics Highlights Aficamten Data at ESC Congress
1M ago
8K
CYTK
Cytokinetics price target raised to $71 from $53 at Barclays
Premium
The Fly
Cytokinetics price target raised to $71 from $53 at Barclays
1M ago
CYTK
Cytokinetics Reveals Promising MAPLE-HCM Trial Results
Premium
Company Announcements
Cytokinetics Reveals Promising MAPLE-HCM Trial Results
1M ago
8K
CYTK

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >